Paclitaxel-eluting coronary stents to improve coronary artery function and prevent restenosis, following coronary angioplasty
Mundy L, Merlin T
Record ID 32006000560
English
Authors' results and conclusions:
Based on the Level II evidence and given that the level of clinical need in the community and the apparent short-term effectiveness of the procedure, it is expected that paclitaxel-eluting stents will diffuse- or are diffusing- rapidly throughout the Australian health system.
Authors' recommendations:
HealthPACT recommends that this technology be referred to the Medical Services Advisory Committee (MSAC) for a full health technology assessment.
Details
Project Status:
Completed
Year Published:
2003
URL for published report:
Not Available
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Stents
- Technology Assessment, Biomedical
- Coronary Artery Disease
- Coronary Restenosis
- Paclitaxel
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.